Bio-Techne's Planned Wilson Wolf Acquisition Underappreciated by Investors, RBC Says

MT Newswires Live05-15

Bio-Techne's (TECH) planned full acquisition of Wilson Wolf is underappreciated by the market, despite its expected boost to Bio-Techne's exposure to cell therapy, RBC Capital Markets said in a note Thursday.

Bio-Techne owns 20% of the cell therapy tools company and plans to fully acquire it by the end of 2027. Assuming that Wilson Wolf maintains its double-digit growth and 70% plus earnings before interest, taxes, depreciation and amortization margins, and the deal is viewed as a "jewel" at about 4.4x trailing sales, the analyst said.

It adds over 100 basis points to Bio-Techne's structural growth and increases its exposure to the cell therapy market to about 15% of sales, the highest in RBC's coverage, despite mixed early results in cell therapy, with activity and pipelines still strong, the analyst said.

"And when the market is ready to look out to 2027, we think investors will wake up to the transformative acquisition of Wilson Wolf that is not yet fully appreciated," the analyst added.

RBC resumed coverage of Bio-Techne with an outperform rating and a $62 price target.

Price: 44.78, Change: +0.04, Percent Change: +0.09

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2635035419?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 23:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635035419","market":"sg","top_or_hot":-1,"title":"Bio-Techne's Planned Wilson Wolf Acquisition Underappreciated by Investors, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Bio-Techne's (TECH) planned full acquisition of Wilson Wolf is underappreciated by the market, despite its expected boost to Bio-Techne's exposure to cell therapy, RBC Capital Markets said in a note Thursday.</p><p>Bio-Techne owns 20% of the cell therapy tools company and plans to fully acquire it by the end of 2027. Assuming that Wilson Wolf maintains its double-digit growth and 70% plus earnings before interest, taxes, depreciation and amortization margins, and the deal is viewed as a \"jewel\" at about 4.4x trailing sales, the analyst said.</p><p>It adds over 100 basis points to Bio-Techne's structural growth and increases its exposure to the cell therapy market to about 15% of sales, the highest in RBC's coverage, despite mixed early results in cell therapy, with activity and pipelines still strong, the analyst said.</p><p>\"And when the market is ready to look out to 2027, we think investors will wake up to the transformative acquisition of Wilson Wolf that is not yet fully appreciated,\" the analyst added.</p><p>RBC resumed coverage of Bio-Techne with an outperform rating and a $62 price target.</p><p>Price: 44.78, Change: +0.04, Percent Change: +0.09</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Techne's Planned Wilson Wolf Acquisition Underappreciated by Investors, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Techne's Planned Wilson Wolf Acquisition Underappreciated by Investors, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-15 23:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Bio-Techne's (TECH) planned full acquisition of Wilson Wolf is underappreciated by the market, despite its expected boost to Bio-Techne's exposure to cell therapy, RBC Capital Markets said in a note Thursday.</p><p>Bio-Techne owns 20% of the cell therapy tools company and plans to fully acquire it by the end of 2027. Assuming that Wilson Wolf maintains its double-digit growth and 70% plus earnings before interest, taxes, depreciation and amortization margins, and the deal is viewed as a \"jewel\" at about 4.4x trailing sales, the analyst said.</p><p>It adds over 100 basis points to Bio-Techne's structural growth and increases its exposure to the cell therapy market to about 15% of sales, the highest in RBC's coverage, despite mixed early results in cell therapy, with activity and pipelines still strong, the analyst said.</p><p>\"And when the market is ready to look out to 2027, we think investors will wake up to the transformative acquisition of Wilson Wolf that is not yet fully appreciated,\" the analyst added.</p><p>RBC resumed coverage of Bio-Techne with an outperform rating and a $62 price target.</p><p>Price: 44.78, Change: +0.04, Percent Change: +0.09</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TECH","symbol_name":"Techne Corporation","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635035419","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635035419","pubTimestamp":1778859966,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Bio-Techne's  planned full acquisition of Wilson Wolf is underappreciated by the market, despite its expected boost to Bio-Techne's exposure to cell therapy, RBC Capital Markets said in a note Thursday.Bio-Techne owns 20% of the cell therapy tools company and plans to fully acquire it by the end of 2027. Assuming that Wilson Wolf maintains its double-digit growth and 70% plus earnings before interest, taxes, depreciation and amortization margins, and the deal is viewed as a \"jewel\" at about 4.4x trailing sales, the analyst said.It adds over 100 basis points to Bio-Techne's structural growth and increases its exposure to the cell therapy market to about 15% of sales, the highest in RBC's coverage, despite mixed early results in cell therapy, with activity and pipelines still strong, the analyst said.\"And when the market is ready to look out to 2027, we think investors will wake up to the transformative acquisition of Wilson Wolf that is not yet fully appreciated,\" the analyst added.RBC ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TECH":"Techne Corporation","TECH.AU":"GLOBAL X MORNINGSTAR GLOBAL","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","BK4121":"生命科学工具和服务","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","ISBC":"投资者银行","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","BK4211":"区域性银行"},"translate_title":"加拿大皇家银行表示，Bio-Techne计划收购Wilson Wolf的计划未得到投资者的重视","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":1.5,"TECH.AU":1,"ISBC":1.5},"content_text":"Bio-Techne's (TECH) planned full acquisition of Wilson Wolf is underappreciated by the market, despite its expected boost to Bio-Techne's exposure to cell therapy, RBC Capital Markets said in a note Thursday.Bio-Techne owns 20% of the cell therapy tools company and plans to fully acquire it by the end of 2027. Assuming that Wilson Wolf maintains its double-digit growth and 70% plus earnings before interest, taxes, depreciation and amortization margins, and the deal is viewed as a \"jewel\" at about 4.4x trailing sales, the analyst said.It adds over 100 basis points to Bio-Techne's structural growth and increases its exposure to the cell therapy market to about 15% of sales, the highest in RBC's coverage, despite mixed early results in cell therapy, with activity and pipelines still strong, the analyst said.\"And when the market is ready to look out to 2027, we think investors will wake up to the transformative acquisition of Wilson Wolf that is not yet fully appreciated,\" the analyst added.RBC resumed coverage of Bio-Techne with an outperform rating and a $62 price target.Price: 44.78, Change: +0.04, Percent Change: +0.09","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2635035419","isCrawlerRequest":true}